Proteomics International Laboratories Ltd - Asset Resilience Ratio

Latest as of December 2025: 57.44%

Proteomics International Laboratories Ltd (PIQ) has an Asset Resilience Ratio of 57.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$6.49 Million
≈ $4.59 Million USD Cash + Short-term Investments

Total Assets

AU$11.30 Million
≈ $7.99 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Proteomics International Laboratories Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Proteomics International Laboratories Lt to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Proteomics International Laboratories Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Proteomics International Laboratories Lt.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$6.49 Million 57.44%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$6.49 Million 57.44%

Asset Resilience Insights

  • Very High Liquidity: Proteomics International Laboratories Ltd maintains exceptional liquid asset reserves at 57.44% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Proteomics International Laboratories Ltd Industry Peers by Asset Resilience Ratio

Compare Proteomics International Laboratories Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 2.34%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%

Annual Asset Resilience Ratio for Proteomics International Laboratories Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Proteomics International Laboratories Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 63.71% AU$9.42 Million
≈ $6.66 Million
AU$14.78 Million
≈ $10.46 Million
+6.70pp
2024-06-30 57.00% AU$6.20 Million
≈ $4.39 Million
AU$10.88 Million
≈ $7.69 Million
-0.47pp
2023-06-30 57.47% AU$5.79 Million
≈ $4.10 Million
AU$10.08 Million
≈ $7.13 Million
+38.94pp
2022-06-30 18.53% AU$1.00 Million
≈ $707.56K
AU$5.40 Million
≈ $3.82 Million
-40.19pp
2021-06-30 58.72% AU$5.05 Million
≈ $3.57 Million
AU$8.60 Million
≈ $6.08 Million
+57.82pp
2020-06-30 0.90% AU$50.00K
≈ $35.38K
AU$5.55 Million
≈ $3.93 Million
-28.10pp
2019-06-30 29.00% AU$1.05 Million
≈ $742.94K
AU$3.62 Million
≈ $2.56 Million
-13.17pp
2018-06-30 42.16% AU$2.32 Million
≈ $1.64 Million
AU$5.49 Million
≈ $3.89 Million
+15.33pp
2017-06-30 26.83% AU$775.14K
≈ $548.46K
AU$2.89 Million
≈ $2.04 Million
--
pp = percentage points

About Proteomics International Laboratories Ltd

AU:PIQ Australia Biotechnology
Market Cap
$18.70 Million
AU$26.43 Million AUD
Market Cap Rank
#25334 Global
#1076 in Australia
Share Price
AU$0.16
Change (1 day)
+14.29%
52-Week Range
AU$0.10 - AU$0.84
All Time High
AU$1.35
About

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more